How much help does a vaccine-induced T-cell response need?

Journal of Clinical Investigation

Volumn 107, Issue 5, 2001, Pages 553-554

  Weber, Jeffrey S ^a   Mulé, James J ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPITOPE; FREUND ADJUVANT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NEU DIFFERENTIATION FACTOR; TUMOR ANTIGEN; TUMOR VACCINE;

BREAST CANCER; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; COVALENT BOND; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; HELPER CELL; IMMUNE RESPONSE; IMMUNOGENICITY; NOTE; PRIORITY JOURNAL; STEM CELL; VACCINATION;

EID: 0035095535     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI12403     Document Type: Note

References (20)

1. A gene encoding an antigen recognized by cytotoxic T lymphocytes on a human melanoma
2. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients
3. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand
4. Granulocyte-macrophagecolony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo
5. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation
6. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine
7. Human HER-2/neu protein immunization circumvents tolerance to rat neu: A vaccine strategy for "self"tumour antigens
8. -) T-cells in humans without foreign helper epitopes
9. Expansion of tumor-Tcell pairs from fine needle aspirates of melanoma metastases
10. Long-term survival of anti-tumor lymphocytes generated by vaccination of patients with melanoma with a peptide vaccine
11. Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses
12. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus
13. Local administration of dendritic cells inhibits established breast tumor growth: Implications for apoptosis-inducing agents
14. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma
15. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine
16. +) T lymphocytes of patients with NY-ESO-1-expressing melanoma
17. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice
18. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
19. Decreased antigen presentation by dendritic cells in patients with breast cancer